CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Pemigatinib After Curative Local Therapy in Locally Advanced Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Rearrangements.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05565794
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:37.203400+00:00
Published At: 2025-04-13T00:00:00+00:00
Record Updated At: 2025-04-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Intrahepatic Cholangiocarcinoma", "FGFR2 Gene Mutation", "FGFR2 Gene Rearrangement", "FGFR2 Gene Translocation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-13"
protocolSection.identificationModule.nctId: "NCT05565794"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Pemigatinib After Curative Local Therapy in Locally Advanced Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Rearrangements."
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.